New generation antipsychotic drugs and compliance behaviour

@article{Voruganti2008NewGA,
  title={New generation antipsychotic drugs and compliance behaviour},
  author={L. Voruganti and Laura K Baker and A. Awad},
  journal={Current Opinion in Psychiatry},
  year={2008},
  volume={21},
  pages={133–139}
}
Purpose of review Antipsychotic therapy has been eclipsed by high rates of noncompliance; the problem was attributed to a lack of efficacy and the burden of side effects of neuroleptics. This review sought to examine whether the arrival of second generation (atypical) antipsychotic drugs with low side-effect liability and improved efficacy has helped to positively reinforce compliance behaviour among people treated for schizophrenia. Recent findings The number of studies that systematically… Expand
Use of long-acting risperidone in psychiatric disorders: focus on efficacy, safety and cost–effectiveness
  • S. Keith
  • Medicine
  • Expert review of neurotherapeutics
  • 2009
TLDR
The efficacy, tolerability and cost–effectiveness of long-acting risperidone in schizophrenia and bipolar disorder patients is discussed, and possibilities for how its role in clinical practice may change over the next 5 years are suggested. Expand
A review of the adverse side effects associated with antipsychotics as related to their efficacy.
TLDR
There is reason to believe that a more personalised approach to antipsychotic treatment should be considered and screening for risk factors, screening for the appearance of side effects, as well as good communication with patients about the side effects and other options available are important tasks for clinicians to optimise concordance with medication. Expand
Attitudes Towards Antipsychotics Among Patients with Schizophrenia on First- or Second-Generation Medications
TLDR
Attitudes were principally determined by severity of side-effects and insight levels, and patients on SGAs had better attitudes, possibly because of less severe side- effects and greater insight among them. Expand
A systematic review of factors influencing adherence to antipsychotic medication in schizophrenia-spectrum disorders
TLDR
It remains difficult to guide clinicians in this vital area and most of the work discussed contained small sample sizes, so future research should prioritise prospective study designs over longer periods and larger samples in naturalistic settings, providing a more appropriate and clinically meaningful framework than widely used cross-sectional designs. Expand
Medical compliance and relapses in schizophrenia: From classical neuroleptics to APAP
TLDR
There has been renewed interest in studying compliance behaviour in recent years propelled by two forces: an exponential growth in the development and testing of new therapeutic agents, and the growing burden of chronic diseases that require reliance on life-long medical treatments. Expand
A STUDY TO ASSESS THE ATTITUDE ON RISK FACTORS ASSOCIATED WITH COMPLIANCE AND NONCOMPLIANCE OF NEUROLEPTIC TREATMENT AMONG PATIENTS WITH SCHIZOPHRENIA
  • 2011
Health is a state of complete harmony of the body, mind and spirit. When one is free from physical disabilities and mental distractions, the gate of the soul open. Non-adherence to prescribedExpand
Assessment of subjective cognitive and emotional effects of antipsychotic drugs. Effect by defect?
TLDR
Antipsychotic treatment appears to be connected to a number of negative subjective effects on cognition and emotion, as well as their association with antipsychotic efficacy on one hand, and adherence rates on the other. Expand
Cure or Curse? Ambivalent Attitudes Towards Neuroleptic Medication in Schizophrenia and Non-Schizophrenia Patients
TLDR
Self-reported neuroleptic non- compliance was more prevalent in psychosis patients than non-psychosis patients, and main reasons for non-compliance in both groups were forgetfulness, distrust in therapist, and no subjective need for treatment. Expand
Antipsychotic treatment beyond antipsychotics: metacognitive intervention for schizophrenia patients improves delusional symptoms
TLDR
The results suggest that the combination of a cognition-oriented and a symptom-oriented approach ameliorate psychotic symptoms and cognitive biases and represents a promising complementary treatment for schizophrenia. Expand
Evaluation of treatment adherence in outpatients with schizophrenia
TLDR
Adequate psychoeducation of patients and their caretakers as well as psychosocial interventions, strengthening mental health infrastructure, and community mental health services will significantly improve treatment adherence in patients with schizophrenia. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 65 REFERENCES
Adherence to atypical antipsychotic treatment among newly treated patients: a population-based study in schizophrenia.
TLDR
Patients who were prescribed their first atypical antipsychotic by a psychiatrist were more likely to be persistent, whereas those with a high comorbidity index and those aged 35 years or more were morelikely to be compliant. Expand
Atypical antipsychotic drugs as a first-line treatment of schizophrenia: a rationale and hypothesis.
TLDR
If the premise that atypical antipsychotic drug provide superior efficacy, reduced side effects, and the prospect of better compliance is accepted, their greatest impact may be when used in patients at the beginning of their illness. Expand
Psychopharmacology: Perspectives on medication adherence and atypical antipsychotic medications.
TLDR
The arrival of atypical antipsychotics, with their lower rate of extrapyramidal effects, was greeted positively as an advance on the older drugs, and it was suggested that the lower rates of side effects would improve compliance, but few data to support this suggestion have been reported. Expand
Effectiveness of atypical antipsychotic medications in reducing violent behavior among persons with schizophrenia in community-based treatment.
TLDR
Treatment with atypical antipsychotic medications should be considered as an important component of violence risk management for schizophrenia patients at risk for violent behavior. Expand
Predictors of antipsychotic medication adherence in patients recovering from a first psychotic episode
TLDR
Beliefs about need for treatment and the benefits of antipsychotic medication may be intervention targets to improve likelihood of long-term medication adherence in patients recovering from a first episode of schizophrenia, schizoaffective, or schizophreniform disorder. Expand
Switching from conventional to novel antipsychotic drugs: results of a prospective naturalistic study
TLDR
Novel antipsychotics emerged as the drug of choice in view of their overall effectiveness, though conventional neuroleptics and clozapine will continue to have a limited but distinct role in the management of schizophrenia. Expand
Adherence to conventional and atypical antipsychotics after hospital discharge.
TLDR
It is suggested that dose frequency is an important predictor of medication adherence and initially appeared to be associated with an adherence advantage over risperidone and conventional antipsychotics, but the apparent advantage may have been due to a usual care dose frequency practice that associated olanzapine more often with once-daily dosing. Expand
Dropout rates in randomised antipsychotic drug trials
TLDR
Trial data implicate that a better compliance can be achieved by favouring atypical drugs rather than conventional alternatives in the treatment of schizophrenia, however, this effect is found only when groups treated with the atypicals antipsychotic clozapine are included in the analysis. Expand
Treatment adherence among patients with schizophrenia treated with atypical and typical antipsychotics
TLDR
Small improvements in adherence intensity among atypical agents do not appear to be clinically important, but may reflect an underlying, stronger tendency to use filled prescriptions. Expand
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
TLDR
Olanzapine was the most effective in terms of the rates of discontinuation, and the efficacy of the conventional antipsychotic agent perphenazine appeared similar to that of quetiapine, risperidone, and ziprasidone. Expand
...
1
2
3
4
5
...